Organic compounds

Kyowa Kirin Announces NOURIANZ™ (Istradefylline) Now Available in the U.S. for Treatment of Parkinson’s Disease “Off” Episodes

Monday, October 14, 2019 - 11:47pm

Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.

Key Points: 
  • Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.
  • To help patients with questions about access to NOURIANZ, Kyowa Kirin offers the Kyowa Kirin Cares program.
  • NOURIANZ (istradefylline) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.
  • Parkinsons disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement and postural instability.

Global Bulk Paclitaxel Market Analysis, Trends, and Forecasts Report 2019-2025 - ResearchAndMarkets.com

Monday, October 14, 2019 - 5:51pm

The "Bulk Paclitaxel - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bulk Paclitaxel - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • Bulk Paclitaxel market worldwide is projected to grow by US$106.2 Million, driven by a compounded growth of 12.1%.
  • Natural Paclitaxel API, one of the segments analyzed and sized in this study, displays the potential to grow at over 11.5%.
  • Poised to reach over US$65.9 Million by the year 2025, Natural Paclitaxel API will bring in healthy gains adding significant momentum to global growth.

Lipocine to Present at the B. Riley NASH Symposium

Monday, October 14, 2019 - 1:00pm

Lipocine's clinical development pipeline includes TLANDO, LPCN 1144, TLANDO XR (LPCN 1111), LPCN 1148 and LPCN 1107 development programs.

Key Points: 
  • Lipocine's clinical development pipeline includes TLANDO, LPCN 1144, TLANDO XR (LPCN 1111), LPCN 1148 and LPCN 1107 development programs.
  • LPCN 1144, a differentiated oral product of bioidentical testosterone, is currently undergoing Phase 2 clinical testing in biopsy confirmed NASH patients and recently completed a proof-of-concept clinical study demonstrating the potential utility the in treatment of NASH.
  • TLANDO XR (LPCN 1111), a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and has completed Phase 2 testing.
  • LPCN 1148 is a unique oral testosterone product targeted to treat NASH cirrhosis.

Flexion Therapeutics Announces Extended FDA Review of Supplemental New Drug Application for ZILRETTA®

Monday, October 14, 2019 - 12:00pm

BURLINGTON, Mass., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA)has informed the company it needs additional time to complete the review of the supplemental New Drug Application (sNDA) for ZILRETTA (triamcinolone acetonide extended-release injectable suspension).

Key Points: 
  • BURLINGTON, Mass., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA)has informed the company it needs additional time to complete the review of the supplemental New Drug Application (sNDA) for ZILRETTA (triamcinolone acetonide extended-release injectable suspension).
  • Although the FDA did not provide a new action date, the FDA informed the company that the review is expected to be completed in the coming weeks.
  • The FDA has not asked for any additional clinical data and the company has provided the FDA with all information requested to date.
  • Indication: ZILRETTA is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

Global 3D Printing Filament Market to 2024 by Material (Plastics, Metals & Ceramics) & End Use (Medical & Dental, Automotive, Consumer Goods, Aerospace & Defense) - ResearchAndMarkets.com

Monday, October 14, 2019 - 11:26am

The global 3D printing filament market is anticipated to grow from $ 2.1 billion in 2018 and reach $ 7.7 billion by 2024, growing at a CAGR of 24.5%.

Key Points: 
  • The global 3D printing filament market is anticipated to grow from $ 2.1 billion in 2018 and reach $ 7.7 billion by 2024, growing at a CAGR of 24.5%.
  • The growth in the market is led by increasing end-use of printing filament in numerous end-use industries and growing awareness about 3D printing technology.
  • The global 3D printing filament market can be segmented based on material, type, end-use and region.
  • Among these types, the plastics sub-segment dominates the global 3D printing filament market, owing to its properties and growing application areas in different end-use industries.

EQUATE Group Announces Official Start-Up of MEGlobal Oyster Creek, TX Site

Monday, October 14, 2019 - 6:00am

OYSTER CREEK, Texas, Oct. 14, 2019 /PRNewswire/ -- Today the EQUATE Group is proud to announce the official start-up of the MEGlobal Oyster Creek Site's commercial production of fiber-grade, on-spec monoethylene glycol.

Key Points: 
  • OYSTER CREEK, Texas, Oct. 14, 2019 /PRNewswire/ -- Today the EQUATE Group is proud to announce the official start-up of the MEGlobal Oyster Creek Site's commercial production of fiber-grade, on-spec monoethylene glycol.
  • The new plant will be operated by MEGlobal Americas Inc., a subsidiary of EQUATE Petrochemical Company and is the Group's first manufacturing facility in the United States.
  • From safety to schedule to cost control, the MEGlobal Oyster Creek Site epitomizes our commitment to operational excellence and efficiency in order to serve the growing customer need for EG across the globe."
  • The MEGlobal Oyster Creek plant is leveraging the U.S. shale gas advantage by utilizing ethylene from the Dow Oyster Creek facility.

Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo

Saturday, October 12, 2019 - 7:32am

Incyte (Nasdaq:INCY) today announces positive 52-week results from its randomized, double-blind, dose-ranging, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor therapy, in adult patients with vitiligo.

Key Points: 
  • Incyte (Nasdaq:INCY) today announces positive 52-week results from its randomized, double-blind, dose-ranging, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor therapy, in adult patients with vitiligo.
  • As we seek to offer a much-needed option for those patients impacted by this life-altering disease, we are excited that the pivotal Phase 3 studies evaluating ruxolitinib cream in patients with vitiligo are underway, with results expected in 2021.
  • Among all patients treated with 1.5 percent ruxolitinib cream BID, the proportion of patients achieving T-VASI50 at Week 52 was 36.4 percent.
  • The safety and efficacy of ruxolitinib cream are being evaluated in an Incyte-sponsored randomized, double-blind, dose-ranging, vehicle-controlled, Phase 2 study (NCT03099304), which began in April 2017.

Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval

Friday, October 11, 2019 - 8:48pm

REYVOW has a unique mechanism of action and is the first and only FDA-approved medicine in a new class of acute treatment for migraine (serotonin (5-HT)1F receptor agonists).

Key Points: 
  • REYVOW has a unique mechanism of action and is the first and only FDA-approved medicine in a new class of acute treatment for migraine (serotonin (5-HT)1F receptor agonists).
  • As with other medicines with central nervous system (CNS) activity, the FDA required abuse potential studies for REYVOW.
  • The REYVOW Phase 3 development program, including the open-label GLADIATOR study, involved more than 4,000 patients and the treatment of more than 20,000 migraine attacks.
  • "The approval of REYVOW is an exciting development for patients and physicians seeking the potential for pain freedom when a migraine attack happens."

Geofoams Market Worth $1,069 Million by 2024 - Exclusive Report by MarketsandMarkets™

Friday, October 11, 2019 - 2:30pm

The road & highway construction segment is projected to lead the geofoams market in terms of both value and volume during the forecast period.

Key Points: 
  • The road & highway construction segment is projected to lead the geofoams market in terms of both value and volume during the forecast period.
  • Based on application, the road & highway construction segment led the geofoams market in 2019 in terms of both value and volume.
  • The expanded polystyrene (EPS) geofoam type segment is projected to lead the geofoams market in terms of both value and volume from 2019 to 2024.
  • Based on type, the expanded polystyrene (EPS) geofoam segment accounted for the largest share of the geofoams market in 2018.

Geofoams Market Worth $1,069 Million by 2024 - Exclusive Report by MarketsandMarkets™

Friday, October 11, 2019 - 2:30pm

The road & highway construction segment is projected to lead the geofoams market in terms of both value and volume during the forecast period.

Key Points: 
  • The road & highway construction segment is projected to lead the geofoams market in terms of both value and volume during the forecast period.
  • Based on application, the road & highway construction segment led the geofoams market in 2019 in terms of both value and volume.
  • The expanded polystyrene (EPS) geofoam type segment is projected to lead the geofoams market in terms of both value and volume from 2019 to 2024.
  • Based on type, the expanded polystyrene (EPS) geofoam segment accounted for the largest share of the geofoams market in 2018.